Laurus Labs Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Laurus Labs kazanç ve gelirin sırasıyla yıllık 55.4% ve 15.9% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 55% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 14.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

55.4%

Kazanç büyüme oranı

55.0%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	17.7%
Gelir büyüme oranı	15.9%
Gelecekteki özkaynak getirisi	14.3%
Analist kapsamı	Good
Son güncelleme	27 Jan 2025

Gelecekteki son büyüme güncellemeleri

Laurus Labs Limited Beat Revenue Forecasts By 7.0%: Here's What Analysts Are Forecasting Next

Jan 27

Laurus Labs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Jan 27

Recent updates

Laurus Labs Limited Beat Revenue Forecasts By 7.0%: Here's What Analysts Are Forecasting Next

Jan 27

These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Extensively

Jan 25

Here's Why It's Unlikely That Laurus Labs Limited's (NSE:LAURUSLABS) CEO Will See A Pay Rise This Year

Jul 05

Laurus Labs Limited's (NSE:LAURUSLABS) Price In Tune With Revenues

Jul 03

Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.40

Apr 28

Laurus Labs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Jan 27

Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?

Dec 01

Laurus Labs (NSE:LAURUSLABS) Is Paying Out Less In Dividends Than Last Year

Oct 22

These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Reasonably Well

Jul 06

Laurus Labs (NSE:LAURUSLABS) Is Paying Out A Dividend Of ₹1.20

Apr 30

Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?

Dec 18

Is Laurus Labs Limited (NSE:LAURUSLABS) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 27

Is Laurus Labs (NSE:LAURUSLABS) Using Too Much Debt?

Sep 09

Laurus Labs (NSE:LAURUSLABS) Has A Somewhat Strained Balance Sheet

Jun 11

Laurus Labs (NSE:LAURUSLABS) Is Paying Out A Larger Dividend Than Last Year

May 02

Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly

Feb 26

With EPS Growth And More, Laurus Labs (NSE:LAURUSLABS) Is Interesting

Feb 11

Does Laurus Labs (NSE:LAURUSLABS) Have A Healthy Balance Sheet?

Nov 26

Laurus Labs (NSE:LAURUSLABS) Is Due To Pay A Dividend Of ₹0.80

Nov 13

I Ran A Stock Scan For Earnings Growth And Laurus Labs (NSE:LAURUSLABS) Passed With Ease

Nov 12

Laurus Labs (NSE:LAURUSLABS) Has Affirmed Its Dividend Of ₹0.80

Oct 30

A Look At The Intrinsic Value Of Laurus Labs Limited (NSE:LAURUSLABS)

Oct 05

Should You Be Adding Laurus Labs (NSE:LAURUSLABS) To Your Watchlist Today?

Aug 10

Kazanç ve Gelir Büyüme Tahminleri

NSEI:LAURUSLABS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	74,882	8,168	3,712	N/A	13
3/31/2026	64,501	5,991	1,586	N/A	13
3/31/2025	55,090	3,230	1,095	N/A	12
12/31/2024	52,733	2,003	N/A	N/A	N/A
9/30/2024	50,532	1,311	-3,277	2,489	N/A
6/30/2024	50,540	1,482	N/A	N/A	N/A
3/31/2024	50,408	1,606	-126	6,657	N/A
12/31/2023	49,821	1,879	N/A	N/A	N/A
9/30/2023	53,320	3,678	2,870	12,248	N/A
6/30/2023	56,834	5,637	N/A	N/A	N/A
3/31/2023	60,406	7,901	37	9,939	N/A
12/31/2022	60,845	9,176	N/A	N/A	N/A
9/30/2022	55,684	8,683	13	8,393	N/A
6/30/2022	51,960	8,374	N/A	N/A	N/A
3/31/2022	49,356	8,275	343	9,111	N/A
12/31/2021	49,227	8,937	N/A	N/A	N/A
9/30/2021	51,823	10,128	-1,705	7,112	N/A
6/30/2021	51,177	10,532	N/A	N/A	N/A
3/31/2021	48,135	9,836	442	7,330	N/A
12/31/2020	42,407	7,971	N/A	N/A	N/A
9/30/2020	36,819	5,977	1,548	5,427	N/A
6/30/2020	32,555	4,120	N/A	N/A	N/A
3/31/2020	28,317	2,553	1,252	3,474	N/A
12/31/2019	26,277	1,883	N/A	N/A	N/A
9/30/2019	24,276	1,326	1,613	3,538	N/A
6/30/2019	23,035	923	N/A	N/A	N/A
3/31/2019	22,919	938	434	2,977	N/A
12/31/2018	22,170	957	N/A	N/A	N/A
9/30/2018	21,665	1,127	N/A	N/A	N/A
6/30/2018	21,168	1,453	N/A	N/A	N/A
3/31/2018	20,562	1,676	N/A	3,425	N/A
12/31/2017	19,687	1,917	N/A	N/A	N/A
9/30/2017	19,954	2,019	N/A	N/A	N/A
6/30/2017	19,733	2,014	N/A	N/A	N/A
3/31/2017	19,046	1,881	N/A	3,320	N/A
3/31/2016	17,776	1,337	N/A	1,820	N/A
3/31/2015	13,266	684	N/A	-647	N/A
3/31/2014	11,597	972	N/A	1,212	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: LAURUSLABS 'nin tahmini kazanç büyümesi (yıllık 55.4% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: LAURUSLABS şirketinin kazançlarının (yıllık 55.4% ) Indian pazarından (yıllık 18.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: LAURUSLABS şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: LAURUSLABS şirketinin gelirinin (yıllık 15.9% ) Indian pazarından (yıllık 11% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: LAURUSLABS şirketinin gelirinin (yıllık 15.9% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: LAURUSLABS 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 14.3 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/02/01 05:06
Gün Sonu Hisse Fiyatı	2025/01/31 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Laurus Labs Limited 22 Bu analistlerden 13, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Prashant Nair	Ambit Capital
Nitin Bhasin	Ambit Capital
null null	Antique Stockbroking Ltd.

Laurus Labs Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 14% to ₹512

Laurus Labs Limited Beat Revenue Forecasts By 7.0%: Here's What Analysts Are Forecasting Next

Consensus EPS estimates fall by 12%

Laurus Labs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Consensus EPS estimates fall by 34%

Price target increased by 7.2% to ₹371

Recent updates

Price target increased by 14% to ₹512

Laurus Labs Limited Beat Revenue Forecasts By 7.0%: Here's What Analysts Are Forecasting Next

Third quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat

These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Extensively

Laurus Labs Limited to Report Q3, 2025 Results on Jan 24, 2025

Laurus Labs Limited's (NSE:LAURUSLABS) P/S Is On The Mark

Consensus EPS estimates fall by 12%

Laurus Labs (NSE:LAURUSLABS) Is Due To Pay A Dividend Of ₹0.40

First half dividend of ₹0.40 announced

Laurus Labs (NSE:LAURUSLABS) Takes On Some Risk With Its Use Of Debt

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited Approves Interim Dividend for the Financial Year 2024- 2025

Laurus Labs Limited to Report Q2, 2025 Results on Oct 24, 2024

Laurus Labs Limited Appoints Ramesh Subrahmanian as A Non-Executive Independent Director

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited to Report Q1, 2025 Results on Jul 25, 2024

Laurus Labs Limited Announces Board Appointments

Here's Why It's Unlikely That Laurus Labs Limited's (NSE:LAURUSLABS) CEO Will See A Pay Rise This Year

Laurus Labs Limited's (NSE:LAURUSLABS) Price In Tune With Revenues

Full year 2024 earnings: EPS misses analyst expectations

Less than half of directors are independent

Less than half of directors are independent

Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.40

Final dividend reduced to ₹0.40

Laurus Labs Limited, Annual General Meeting, Jul 11, 2024

Full year 2024 earnings: EPS misses analyst expectations

Laurus Labs Limited Approves Board Changes

Laurus Labs Limited to Report Q4, 2024 Results on Apr 25, 2024

Laurus Labs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited to Report Q3, 2024 Results on Jan 24, 2024

Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?

Consensus EPS estimates fall by 34%

Upcoming dividend of ₹0.40 per share at 0.4% yield

Price target increased by 7.2% to ₹371

Laurus Labs (NSE:LAURUSLABS) Is Paying Out Less In Dividends Than Last Year

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited Approves Interim Dividend, Payable on or After November 09, 2023

Laurus Labs Limited to Report Q2, 2024 Results on Oct 20, 2023

Laurus Labs Limited (NSEI:LAURUSLABS) agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million.

Investor sentiment improves as stock rises 16%

Consensus EPS estimates fall by 10%

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: ₹0.46 (vs ₹4.68 in 1Q 2023)

These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited (NSEI:LAURUSLABS) signed an investment agreement to acquire additional 7.24% stake in Immunoadoptive Cell Therapy Private Limited for INR 800 million.

Upcoming dividend of ₹1.20 per share at 0.6% yield

Price target decreased by 11% to ₹382

Laurus Labs (NSE:LAURUSLABS) Is Paying Out A Dividend Of ₹1.20

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 10% to ₹470

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Laurus Labs Limited to Report Q3, 2023 Results on Jan 30, 2023

Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?

Laurus Labs Limited announced that it expects to receive INR 38.998 million in funding from Ethan Energy India Private Limited

Insufficient new directors

Upcoming dividend of ₹0.80 per share

Price target decreased to ₹574

Laurus Labs Limited Approves Interim Dividend for the Financial Year 2022-2023, Payable on or After November 15, 2022

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited to Report Q2, 2023 Results on Oct 21, 2022

Is Laurus Labs Limited (NSE:LAURUSLABS) Expensive For A Reason? A Look At Its Intrinsic Value

Is Laurus Labs (NSE:LAURUSLABS) Using Too Much Debt?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Laurus Labs Limited to Report Q1, 2023 Results on Jul 27, 2022

Investor sentiment deteriorated over the past week

Laurus Labs (NSE:LAURUSLABS) Has A Somewhat Strained Balance Sheet

Full year 2022 earnings: Revenues and EPS in line with analyst expectations